.Merck beats profits assumptions, brings up sales overview on solid need for top medications like Keytruda CNBCMerck & Co. (MRK US) Beats Revenue Estimates as Keytruda Sales Increase BloombergMerck Stock: Pharma Titan Posts Solid Outcomes, However Outlook Drops Short Real estate investor's Service DailyMerck Announces Second-Quarter 2024 Financial End results Yahoo FinanceMerck defeats revenue as well as sales requirements in the middle of Keytruda strong point, but offers blended full-year expectation MarketWatch.